Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

1. Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable

Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable 1 Driving better decision-making in healthcare Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable Technology Guidance from the MOH Drug Advisory Committee Published on 1 April 2020 Guidance recommendations The Ministry of Health’s Drug Advisory Committee has recommended: ? ? omeprazole 40 mg injection; and ? pantoprazole 40 mg (...) 1.2 1.3 The MOH Drug Advisory Committee (“the Committee”) considered the evidence presented for the technology evaluation of intravenous proton pump inhibitors (IV PPIs) for gastric anti-secretory treatment. The Agency for Care Effectiveness conducted the evaluation in consultation with clinical experts from public healthcare institutions. Published clinical and economic evidence for IV omeprazole, esomeprazole and pantoprazole was considered in line with their registered indications. The evidence

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

2. The overuse of proton pump inhibitors: implications for prescribing physicians

. Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Alimentary pharmacology & therapeutics. 2005;21(2):149-154. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therapeutic Advances in Gastroenterology. 2012;5(4):219-232. Ksiadzyna D, Szelag A, Paradowski L. Overuse of proton pump inhibitors. Polskie Archiwum Medycyny Wewnetrznej. 2015;125(4):289-298 (...) The overuse of proton pump inhibitors: implications for prescribing physicians The Overuse of Proton Pump Inhibitors: Implications for Prescribing Physicians – Clinical Correlations Search The Overuse of Proton Pump Inhibitors: Implications for Prescribing Physicians October 15, 2019 7 min read By Matthew Kingery Peer Reviewed Proton pump inhibitors (PPIs), frequently prescribed for dyspepsia and other acid-related disorders, are one of the most commonly used medications in the US. As of 2012

2019 Clinical Correlations

3. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Full Text available with Trip Pro

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies. We aimed to confirm these findings in an adequately powered randomized trial.We performed a 3 × 2 partial factorial double-blind trial of 17,598 participants

2019 EvidenceUpdates

4. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. Full Text available with Trip Pro

Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. To estimate all cause mortality and cause specific mortality among patients taking proton pump inhibitors (PPIs).Longitudinal observational cohort study.US Department of Veterans Affairs.New users of PPIs (n=157 625) or H2 blockers (n=56 842).All cause mortality and cause specific mortality associated with taking PPIs (values reported as number of attributable

2019 BMJ

5. Trends in utilization of proton pump inhibitors in British Columbia

to the upper gastrointestinal tract, a common presentation to the primary care physi- cian. 1-3 These Letters reviewed evidence about H 2 -block- ers, eradication of Helicobacter pylori, and drugs used for gastroesophageal reflux. However, they also raised concerns about chronic acid suppression by daily dosing of omeprazole, the first proton pump inhibitor (PPI) on the Canadian market. By 1994 there was already concern that long-term proton pump inhibition could be problem- atic. Since (...) Trends in utilization of proton pump inhibitors in British Columbia Trends in utilization of proton pump inhibitors in British Columbia February - March 2019 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 118 T he first three Therapeutics Letters focused on com - plaints related

2019 Therapeutics Letter

6. Proton pump inhibitors: increased mortality

Proton pump inhibitors: increased mortality Prescrire IN ENGLISH - Spotlight ''Proton pump inhibitors: increased mortality'', 1 January 2019 {1} {1} {1} | | > > > Proton pump inhibitors: increased mortality Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Proton pump inhibitors: increased mortality FEATURED REVIEW Proton pump inhibitors (PPIs (...) ) such as omeprazole are used in oesophagitis, gastroesophageal reflux disease and peptic ulcer disease. PPIs have few severe adverse effects in the short term. But this is not the case in the long term. Full review (3 pages) available for download by subscribers. Abstract Proton pump inhibitors (PPIs) are widely used in oesophagitis, gastroesophageal reflux disease and peptic ulcer disease. They provoke few severe adverse effects in the short term, but this is not the case in the long term (infections, fractures

2019 Prescrire

7. Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication

Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication © The Author(s) 2018. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 1 Editorial Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor T reatment (...) and Gastric Cancer after Helicobacter pylori Eradication A recent paper by Cheung et al. (1) reported that long-term use of proton pump inhibitors (PPIs) was associated with an increased risk of gastric cancer “even after” Helicobacter pylori (H. pylori) eradication. This has created significant concerns among physicians and patients (2). The Canadian Association of Gastroenterology (CAG) has serious reservations about the validity of this study and, hence, considers it important to provide guidance

2019 Canadian Association of Gastroenterology

8. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. Full Text available with Trip Pro

Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. Anticoagulant choice and proton pump inhibitor (PPI) cotherapy could affect the risk of upper gastrointestinal tract bleeding, a frequent and potentially serious complication of oral anticoagulant treatment.To compare the incidence of hospitalization for upper gastrointestinal tract bleeding in patients using individual anticoagulants with and without PPI

2018 JAMA

9. Core IM: 5 pearls on proton pump inhibitors

Core IM: 5 pearls on proton pump inhibitors Core IM: 5 Pearls on PPIs – Clinical Correlations Search Core IM: 5 Pearls on PPIs August 29, 2018 15 min read Podcast: | Subscribe: | By Cary Blum MD, Marty Fried MD and Shreya P. Trivedi MD || Illustration by Michael Shen MD. Quiz yourself on the 5 Pearls we will be covering: What are associated adverse effects for patients are on long-term PPIs? (2:02) What are some strategies to get your patient off PPIs? (10:57) How do histamine-2 (H2) receptor (...) have a great graphic of the physiology that might be helpful to follow along with on any of our social media C: Great. So remember that gastric acid is secreted by what cells? M: Umm… Stomach cells? C: Ummm, yes… but more specifically [pause for beat] parietal cells [M: ahhhhh]. They have the hydrogen-potassium ATPase – otherwise known as… S: the proton pump! C: That’s right! The infamous proton pump – purveyor of agida, head honcho of heartburn, the regal ruler of the reflux regime, the- you guys

2018 Clinical Correlations

10. Proton pump inhibitors

Proton pump inhibitors Top results for proton pump inhibitors - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look (...) like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for proton pump inhibitors The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials

2018 Trip Latest and Greatest

11. Deprescribing Proton Pump Inhibitors

Deprescribing Proton Pump Inhibitors Deprescribing Proton Pump Inhibitors March - April 2018 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 111 T he first PPI was approved in Canada in 1988. Pronounced and durable reduction of stomach acid production made omeprazole a “blockbuster (...) Inhibitors. Therapeutics Letter. 2016 (Mar-Apr); 99:1-2. 10. Gomm W , von Holt K, Thom F et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol. 2016;73(4):410-6. DOI:10.1001/jamaneurol.2015.4791 11. Filion KB, Chateau D, Targownik LE et al. Proton pump inhibitors and the risk of hospitalization for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014; 63(4):552-558. DOI:10.1136/gutjnl-2013-304738 12

2018 Therapeutics Letter

12. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults Full Text available with Trip Pro

Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults To estimate associations between long-term use of proton pump inhibitors (PPIs) and pneumonia incidence in older adults in primary care.Longitudinal analyses of electronic medical records.England PARTICIPANTS: Individuals aged 60 and older in primary care receiving PPIs for 1 year or longer (N=75,050) and age- and sex-matched controls (N=75,050).Net hazard ratios for pneumonia incidence in Year 2

2018 EvidenceUpdates

13. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014) Full Text available with Trip Pro

No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014) Proton pump inhibitors (PPIs) are commonly used medications. Recent studies reported an increased risk of acute myocardial infarction (MI) in PPI users vs non-users. We evaluated MI risk associated with PPIs compared with histamine-2 receptor antagonists (H2RAs) in privately insured adults in the United States.Using administrative

2018 EvidenceUpdates

14. Proton Pump Inhibitors: Are They a Real Threat to the Patient? Full Text available with Trip Pro

Proton Pump Inhibitors: Are They a Real Threat to the Patient? Proton pump inhibitors are among the most frequently prescribed drugs in the world and are generally considered safe. However, there is growing concern regarding their safety.A nonsystematic review of the current literature was performed regarding proton pump inhibitors and their adverse effects. Proton pump inhibitors seem to be associated with fundic gland polyp development (without clinical relevance) and Clostridium difficile (...) infection. Also, in cirrhotic patients, their prescription should be carefully reviewed. Regarding their association with other enteric infections, micronutrient deficiency, dementia, and chronic kidney disease, current evidence is still of low quality, and further studies are needed.Considering the current evidence, most patients with a clear clinical indication for proton pump inhibitor treatment should probably benefit from the maintenance of their treatment without significant adverse effects

2018 GE Portuguese journal of gastroenterology

15. General medicine: Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer

General medicine: Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer Article Text Commentary General medicine

2018 Evidence-Based Medicine

16. Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines

Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines Non-Pharmacological Alternatives to Proton Pump Inhibitors: Comparative Clinical Effectiveness and Guidelines Last updated: May (...) 11, 2018 Project Number: RB1217-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the comparative clinical effectiveness of non-pharmacological or alternative interventions compared to proton pump inhibitors for patients with disorders of excessive acid secretion? What are the evidence-based guidelines for non-pharmacological or alternative interventions for patient with excessive acid secretion? Key Message One non

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. A Clinical Trial of Proton Pump Inhibitors to Treat Children with Chronic Otitis Media with Effusion. Full Text available with Trip Pro

A Clinical Trial of Proton Pump Inhibitors to Treat Children with Chronic Otitis Media with Effusion. Gastroesophageal reflux (GER) is considered a cause of otitis media with effusion (OME). This study aimed to investigate whether OME can be effectively treated with a proton pump inhibitor (PPI), therefore implicating GER as a causative factor of OME.A PPI or placebo was randomly administered to enrolled subjects for 4-8 weeks. To monitor effusion status, subjects underwent monthly pneumatic

2018 The journal of international advanced otology Controlled trial quality: uncertain

18. Pneumonia caused by proton pump inhibitors (PPI)

ATPase regulates surfactant secretion in rat alveolar type II cells by modulating lamellar body calcium. PLoS One. 2010 Feb 16;5(2):e9228. PMID:20169059 13) Bidani A, et al. Bactericidal activity of alveolar macrophages is suppressed by V-ATPase inhibition. Lung. 2000;178(2):91-104. PMID: 10773135Page 42 · MED CHECK - TIP December 2017/ Vol.3 No.9 Pneumonia caused by proton pump inhibitor (PPI): Translated from MedCheckTIP in Japanese Mov 2017 : 17(74):131-132 (2) Critical appraisal of a study using (...) Pneumonia caused by proton pump inhibitors (PPI) MED CHECK - TIP December 2017 / Vol.3 No.9 · Page 27 -The Informed Prescriber C N o 9 M ED HECK D e ce m b e r 2 0 1 7 WHO downgrades Tamiflu Suvorexant : A hypnotic causing cataplexy Insomnia, Sleep Duration, Harm of hypnotics PPI causes Pneumonia Editorial WHO downgraded oseltamivir (Tamiflu) New Products Hypnotic (sleeping pill), suvorexant (brand name Belsomra) A substance that causes narcolepsy and cataplexy Teriparatide More harm than

2018 Med Check - The Informed Prescriber

19. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study Full Text available with Trip Pro

Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study Proton pump inhibitors (PPIs) is associated with worsening of gastric atrophy, particularly in Helicobacter pylori (HP)-infected subjects. We determined the association between PPIs use and gastric cancer (GC) among HP-infected subjects who had received HP therapy.This study was based on a territory-wide health database of Hong Kong. We identified adults who

2017 EvidenceUpdates

20. Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients Full Text available with Trip Pro

Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients Long-term inappropriate proton pump inhibitors use (PPIs) is a matter of concern because of the risks associated with their long-term use in older patients with chronic conditions. The risk of PPI treatment in hemodialysis patients remains unexplored.We assessed the relationship between the use of PPIs and the risk of death in hemodialysis patients throughout a retrospective multicenter propensity score-matched study

2017 Kidney international reports